CVR 37303496Entrepreneurial company (IVS)Forskning og eksperimentel udvikling indenfor bioteknologi (721100)Malmmosevej 19, 2840 HolteFounded 14 Dec 2015
Cell-useper IVS
CVR registers no owner holding 5% or more.
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Cell-useper IVS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexRevenue
0
DKK, annual report 2016
Result
0
DKK, annual report 2016
Equity
1
DKK, annual report 2016
CVR registers no owner holding 5% or more.
Per Stobbeuntil 11 Sep 2017
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2016 |
|---|---|
| Revenue | 0 |
| Operating profit | 0 |
| Result for the year | 0 |
| Equity | 0 |
| Total assets | 0 |
2016 covers 13 months (14 Dec 2015 to 31 Dec 2016).
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingCashPaid in 1 | None | 1 | None | 1 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2016 |
|---|---|
| EBITDA | 0 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. |
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. |
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. |
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. |
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. |
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. |
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Source: CVR, read 20 Nov 2026.
3 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Virksomheden er opløst ved erklæring, jf. selskabslovens § 216
Direktion:
Fratrådte:
Per Stobbe (adm. dir), den 11.09.2017.
Vedtægter ændret: 02.02.2017
Nyt navn: Cell-useper IVS
Stiftelsesdato: 14.12.2015.
Seneste vedtægtsdato: 14.12.2015.
Kapital:
kr. 1,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 1,00 til kurs 100,00, fuldt indbetalt.
Stifter:
CVR-NR. 19805476 STOBBE TECH A/S, Malmmosevej 19C, 2840 Holte, den 14.12.2015.
Direktion:
Per Stobbe, (adm. dir), CH-6830 Chiasso, Schweiz, Svejts, den 14.12.2015.
Virksomheden tegnes af direktionen..
Første regnskabsår:
14.12.2015 - 31.12.2016.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive industriel forsknings- og fremstillingsvirksomhed samt handel med produktionsanlæg til medicinfremstilling og hermed forbunden virksomhed.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 20 Nov 2026.
What Pro holds for Cell-useper IVS:
Have Pro? Sign in.
P-number 1020981926Malmmosevej 19, 2840 Holte